News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cyclacel Pharmaceuticals, Inc. (CYCC)'s Sapacitabine Reported to Have Anti-Tumor Activity Against Ovarian Cancer


9/20/2013 9:59:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERKELEY HEIGHTS, N.J., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced updated data showing that sapacitabine has activity against a majority of ovarian cancer samples taken from patients, including resistant tumors. The data were reported at a poster presentation during the American Association of Cancer Research (AACR) conference "Advances in Ovarian Cancer: from concept to clinic" being held September 18-21, 2013, in Miami, FL.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES